Time To Go Global: Remote Possibilities

 

 

EdTech vendors have been good corporate citizens by offering free resources during this year’s school closures, but eventually they need revenue to keep the doors open. According to industry vendor Michael Spencer, CEO of Global Expansion Strategies, and former Senior Director of International Business Development at K12, the opportunity is ripe to find new revenue streams around the world. In this episode of Remote Possibilities, Michael breaks down some of the ways to get started:

Understand the Market You’re Looking to Enter

In the United States, the decision-making on edTech purchases is fragmented. In the international space, by contrast, the decision-making is usually led by a very small team, which gives edTech providers a better chance to establish a relationship and offer a comprehensive vision of what you can offer.

Engage Schools, Parents, and Students

For companies that are new to a given territory, extolling the features of your product just won’t cut it. You’ve got to be ready and eager to explain how everybody that touches it will benefit. You not only have to get the buy-in from teachers and administrators at the school itself, but also from parents and students. All of these stakeholders must clearly understand how optimal student outcomes can be achieved upon implementation in the school. That requires you to not just sell, but to go the extra mile and explain how your solution or technology is supposed to be implemented and managed. You can share this information via professional development at the school, and the school can then pass it on to the parents.

Be Ready with Multiple Delivery Methods

Because we still don’t know exactly what school will look like in the fall, I strongly suggest that companies develop multiple blended learning models in which their content can be delivered, either in class, online, or in some combination of the two.

To read more of Spencer’s thoughts, click here.

Catch Up on Previous Episodes of Remote Possibilities!

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More